509 related articles for article (PubMed ID: 33103852)
41. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Aldinucci D; Borghese C; Casagrande N
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096713
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
Özdemir S; Ton Ö; Kabukcuoğlu F
Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
[TBL] [Abstract][Full Text] [Related]
43. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Aldinucci D; Celegato M; Casagrande N
Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy.
Lin HC; Chang Y; Chen RY; Hung LY; Chen PC; Chen YP; Medeiros LJ; Chiang PM; Chang KC
Cancer Sci; 2021 Apr; 112(4):1589-1602. PubMed ID: 33525055
[TBL] [Abstract][Full Text] [Related]
45. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
46. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
47. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Skinnider BF; Elia AJ; Gascoyne RD; Patterson B; Trumper L; Kapp U; Mak TW
Blood; 2002 Jan; 99(2):618-26. PubMed ID: 11781246
[TBL] [Abstract][Full Text] [Related]
48. Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma.
Adam M; Bekuretsion Y; Gebremedhin A; Kwiecinska A; Howe R; Petros B; Jerkeman M
J Clin Exp Hematop; 2023; 63(4):230-239. PubMed ID: 38148013
[TBL] [Abstract][Full Text] [Related]
49. Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease.
Spieker T; Kurth J; Küppers R; Rajewsky K; Bräuninger A; Hansmann ML
Blood; 2000 Nov; 96(9):3133-8. PubMed ID: 11049994
[TBL] [Abstract][Full Text] [Related]
50. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
51. [Factors involved in host-pathogen interaction for the risk of Hodgkin lymphoma induced by Epstein Barr virus].
Torres Espíndola LM; Arellano Galindo J; Velazquez Cruz R; Castillejos López Mde J
Invest Clin; 2013 Sep; 54(3):311-24. PubMed ID: 24354244
[TBL] [Abstract][Full Text] [Related]
52. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease.
Oudejans JJ; Jiwa NM; Kummer JA; Horstman A; Vos W; Baak JP; Kluin PM; van der Valk P; Walboomers JM; Meijer CJ
Blood; 1996 May; 87(9):3844-51. PubMed ID: 8611711
[TBL] [Abstract][Full Text] [Related]
53. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
54. New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease.
Reynolds DJ; Banks PM; Gulley ML
Am J Pathol; 1995 Feb; 146(2):379-88. PubMed ID: 7531953
[TBL] [Abstract][Full Text] [Related]
55. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
56. Analysis of a clonally related mantle cell and Hodgkin lymphoma indicates Epstein-Barr virus infection of a Hodgkin/Reed-Sternberg cell precursor in a germinal center.
Tinguely M; Rosenquist R; Sundström C; Amini RM; Küppers R; Hansmann ML; Bräuninger A
Am J Surg Pathol; 2003 Nov; 27(11):1483-8. PubMed ID: 14576485
[TBL] [Abstract][Full Text] [Related]
57. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.
Piris MA; Medeiros LJ; Chang KC
Pathology; 2020 Jan; 52(1):154-165. PubMed ID: 31699300
[TBL] [Abstract][Full Text] [Related]
58. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
59. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
[TBL] [Abstract][Full Text] [Related]
60. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.
Kis LL; Nishikawa J; Takahara M; Nagy N; Matskova L; Takada K; Elmberger PG; Ohlsson A; Klein G; Klein E
Int J Cancer; 2005 Mar; 113(6):937-45. PubMed ID: 15514968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
